Gensenoside Rg3 inhibits hypoxia-induced VEGF expression in human cancer cells

Qing-Jiang Chen, Ming-Zhi Zhang, Lexin Wang

Research output: Contribution to journalArticlepeer-review

60 Citations (Scopus)
19 Downloads (Pure)


Aims: The ginsenoside Rg3 (Rg3) inhibits xenograft growth and angiogenesis in tumors mainly via down-regulates VEGF expression. This study was designed to investigate the mechanisms by which Rg3 down-regulates VEGF expression. Methods: MTT assay was performed to investigate the effect of Rg3 on the growth of human esophageal carcinoma cell line Eca-109 and 786-0 cells under normoxic and hypoxic conditions. ELISA was used to detect VEGF protein secreted by the cells under normoxic and hypoxic conditions. Real-time quantitative reverse transcriptase polymerase chain reaction and Western blotting were used to detect gene expression and protein synthesis. Results: Rg3 inhibited Eca-109 and 786-0 cell proliferation and induced a significant reduction in VEGF mRNA under hypoxia conditions. Rg3 treatment inhibited hypoxia-induced expression HIF-1', COX-2 and NF-'B under normoxic and hypoxic conditions. Treatment with Rg3 reduced the hypoxia-induced phosphorylation of STAT3 in a dose-dependent manner in the both cell lines. Rg3 treatment also inhibited the phosphorylation of ERK1/2 and JNK induced by hypoxia. Conclusions: Rg3 targets hypoxia-induced multiple signaling pathways to down-regulate VEGF expression in cancer cells. These actions may contribute to the overall efficacy of Rg3 against tumor angiogenesis and growth.
Original languageEnglish
Pages (from-to)849-858
Number of pages10
JournalCellular Physiology and Biochemistry
Issue number6
Publication statusPublished - 2010

Fingerprint Dive into the research topics of 'Gensenoside Rg3 inhibits hypoxia-induced VEGF expression in human cancer cells'. Together they form a unique fingerprint.

Cite this